07:00 , Oct 10, 2016 |  BioCentury  |  Emerging Company Profile

Pellino play

Bridge Biotherapeutics Inc. has licensed the first of what it hopes will be many assets it can use its translational expertise to bring through Phase II proof of concept. The South Korean company is seeking...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

AnGes, BioLeaders, GenoLac deal

AnGes received exclusive, worldwide rights to develop and commercialize GenoLac's and BioLeader's HPV vaccine candidate to prevent cervical intraepithelial neoplasia. AnGes already has rights in China. The vaccine targets the E7 transforming protein (Human papillomavirus-16;...
07:00 , Apr 16, 2012 |  BC Week In Review  |  Company News

AnGes, BioLeaders deal

The companies partnered to develop an oral DNA vaccine to treat hypertension. The vaccine will target the angiotensin II type 1 (AT1) receptor (AGTR1) and the AT2 receptor. It uses DNA vaccine technology from Osaka...
00:07 , Apr 13, 2012 |  BC Extra  |  Company News

AnGes, BioLeaders to develop oral hypertension vaccine

AnGes MG Inc. (Tokyo:4563) and BioLeaders Corp. Co. Ltd. (Daejeon, South Korea) partnered to develop an oral DNA vaccine to treat hypertension. The vaccine will target the angiotensin II type 1 (AT1) receptor (AGTR1) and...